Luminal‐B and HER2‐enriched patients had more advanced tumors (tumor size >5 cm: 14.1% and 11.6% vs 7.7% and 9.6%, respectively; P < 0.001) than luminal‐A and triple‐negative patients. The gene discussed is ERBB2; the disease is neoplasm.